Clinical TrialJun 15, 2026, 08:01 AM
Neumora Discontinues Navacaprant After Phase 3 Failure; Cuts 35% Workforce
AI Summary
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies for navacaprant in major depressive disorder did not achieve statistical significance on primary or key secondary endpoints, leading to the discontinuation of its development. Following this, the company will reduce its workforce by approximately 35%, expecting annualized cost savings of about $10 million, offset by $2 million in one-time restructuring costs. Neumora projects its cash runway to extend into the third quarter of 2027 and will focus on advancing other pipeline programs, including NMRA-511, NMRA-898, and NMRA-215, with anticipated milestones over the next 12 months.
Key Highlights
- Navacaprant failed primary and key secondary endpoints in KOASTAL-2 and -3 Phase 3 studies for MDD.
- Company to discontinue development of navacaprant.
- Workforce reduced by approximately 35%.
- Expected annualized cost savings of approximately $10 million.
- One-time restructuring costs of approximately $2 million.
- Cash runway extended into the third quarter of 2027.
- KOASTAL-2: navacaprant 80 mg (n=217) vs placebo (n=213), LSMD = -0.3 (p=0.813).
- KOASTAL-3: navacaprant 80 mg (n=212) vs placebo (n=210), LSMD = 0.7 (p=0.480).
Price Impact
More from NMRA